Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 181 to 190 of 2450 total matches.
Acetaminophen Safety - Deja Vu
The Medical Letter on Drugs and Therapeutics • Jul 13, 2009 (Issue 1316)
hepatotoxicity be added to the labeling for
acetaminophen.
1
ANALGESIC EFFECTIVENESS — Mild to moderate
pain ...
Concerns have surfaced again at the FDA and in the media about the safety of acetaminophen and the multiplicity of products on the market in the US that contain various amounts of it.
Adapalene for Acne
The Medical Letter on Drugs and Therapeutics • Feb 28, 1997 (Issue 995)
, has been marketed in the USA
in a 0.1% gel formulation for topical treatment of acne vulgaris.
PHARMACOLOGY ...
Adapalene (Differin - Galderma), a synthetic retinoid analog, has been marketed in the USA in a 0.1% gel formulation for topical treatment of acne vulgaris.
Homeopathic Products
The Medical Letter on Drugs and Therapeutics • Feb 26, 1999 (Issue 1047)
protocols
for preparing more than 1,200 substances for homeopathic use (Homœopathic Pharmacopœia ...
Some patients may ask physicians about the effectiveness and safety of homeopathic drugs, which are marketed through health food stores, pharmacies, direct mail and person-to-person sales, and promoted for use in a wide range of disorders.
In Brief: Semglee - A New Insulin Glargine for Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 25, 2021 (Issue 1616)
), an insulin
glargine product similar to Lantus, for treatment of
type 1 diabetes in children and adults ...
The FDA has approved Semglee (Mylan), an insulin
glargine product similar to Lantus, for treatment of
type 1 diabetes in children and adults and type 2
diabetes in adults. Semglee is the second "follow-on"
insulin glargine product to become available in
the US; Basaglar, which is also similar to Lantus, was
the first. Lantus is a recombinant analog of human
insulin that forms microprecipitates in subcutaneous
tissue, prolonging its duration of action to a mean of
about 24 hours with no pronounced peak effect.
Drugs for Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • Dec 02, 2019 (Issue 1586)
is reviewed in a separate issue.1
In general, all eye drops should be given in doses of one
drop ...
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate issue.
Automated External Defibrillators
The Medical Letter on Drugs and Therapeutics • Aug 14, 2006 (Issue 1241)
cardiac arrest has a survival rate of about 6%
without immediate defibrillation.
1
Automated external ...
Sudden cardiac arrest has a survival rate of about 6% without immediate defibrillation. Automated external defibrillators (AEDs) can be found in many public locations such as shopping malls, office buildings and schools. Some patients may ask their physicians whether they should purchase an AED for personal use. One device has been FDA-approved for sale over the counter (HeartStart Home Defibrillator - Philips). Purchase of all other AEDs for public places or home use requires authorization from a physician.
Metformin/Repaglinide (PrandiMet) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Jun 01, 2009 (Issue 1313)
)
June 1, 2009
www.medicalletter.org
Published by The Medical Letter, Inc. • 1000 Main Street, New ...
A new fixed-dose tablet (PrandiMet - Novo Nordisk) combining metformin (Glucophage, and others) and repaglinide (Prandin) has been approved by the FDA for treatment of type 2 diabetes in patients already taking both metformin and repaglinide, or for patients not adequately controlled on either drug alone.
Ozanimod (Zeposia) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple ...
The FDA has approved ozanimod (Zeposia – Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological episode), relapsing-remitting
disease, and active secondary progressive MS
(SPMS). It is the third oral S1P receptor modulator to
be approved in the US for treatment of relapsing forms
of MS; siponimod (Mayzent) is also indicated for use
in adults, and fingolimod (Gilenya) is approved for use
in patients ≥10 years old.
Brodalumab (Siliq) - Another IL-17A Antagonist for Psoriasis
The Medical Letter on Drugs and Therapeutics • Jul 17, 2017 (Issue 1525)
earlier.1,2
STANDARD TREATMENT — Plaque psoriasis is
a chronic, inflammatory, immune-mediated skin ...
The FDA has approved brodalumab (Siliq – Valeant),
an injectable human interleukin (IL)-17A receptor
antagonist, for treatment of adults with moderate to
severe plaque psoriasis who have failed to respond
to other systemic therapies. Brodalumab is the third
IL-17A antagonist to be approved in the US for this
indication; secukinumab (Cosentyx) and ixekizumab
(Taltz) were approved earlier.
Fiasp - Another Insulin Aspart Formulation for Diabetes
The Medical Letter on Drugs and Therapeutics • Jan 01, 2018 (Issue 1537)
Fiasp – Another Insulin Aspart
Formulation for Diabetes
Table 1. Rapid-Acting Insulins
Some ...
The FDA has approved Fiasp (Novo Nordisk), a new
formulation of insulin aspart, to improve glycemic
control in adults with diabetes. Fiasp is described by
the manufacturer as faster-acting than conventional
insulin aspart (Novolog).